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Background: Lungs of cystic ﬁbrosis (CF) patients are chronically infected with
Pseudomonas aeruginosa. Increased airway constriction has been reported in CF pa-
tients but underplaying mechanisms have not been elucidated.
Aim: Examine the effect of P. aeruginosa LPS on airway constriction in CF mice
and the implication in this process of cytosolic phospholipase A2a (cPLA2a),
involved in arachidonic acid (AA) release.
Methods: Mice were instilled intranasally with LPS. Airway constriction was
assessed using barometric plethysmograph. MIP-2, prostaglandin E2 (PGE2),
leukotrienes and AA concentrations were measured in BALF using standard kits
and gas chromatography.
Results: LPS induced enhanced airway constriction and AA release in BALF
of CF compared to littermate mice. This was accompanied by increased levels
of PGE2, but not those of leukotrienes. However, airway neutrophil inﬂux and
MIP-2 production remained similar in both mouse strains. The cPLA2a inhibitor
arachidonyl triﬂuoro-methyl-ketone (ATK), but not aspirin, which inhibit PGE2
synthesis, reduced LPS-induced airway constriction. LPS induced lower airway
constriction in cPLA2a −/− mice compared to corresponding littermates. Neither
aspirin, nor ATK interfered with LPS-induced airway neutrophil inﬂux or MIP-2
production.
Conclusions: CF mice develop enhanced airway constriction through a cPLA2a-
dependent mechanism. Airway inﬂammation is dissociated from airway constriction
in this model. cPLA2a may represent a suitable target for therapeutic intervention in
CF. Attenuation of airway constriction by cPLA2a inhibitors may help to ameliorate
the clinical status of CF patients.
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Microparticles (MPs) are membrane vesicles that are released during cell activation
and apoptosis. MPs have different biological effects depending on the cell from they
originate. Cystic ﬁbrosis (CF) lung disease is characterized by massive neutrophil
inﬂux in the airways, their activation and eventually apoptosis. We investigated on
the presence and phenotype of MPs in the sputum, a rich noninvasive source of
inﬂammation biomarkers, of acute and intermittent CF adult patients. Spontaneous
sputum, obtained from 21 CF patients (10 acute and 11 intermittent) and 7 patients
with primary ciliary diskinesia (PCD), was liqueﬁed with Sputasol. MPs were
counted and identiﬁed in the supernatants of treated sputum by cytoﬂuorimetry and
immunodecoration for leukocyte (CD11a), granulocyte (CD66b), and monocyte-
macrophage (CD11b) antigens. CF sputa contained higher number of MPs in
comparison with PCD sputa. CD66b and CD11a, but not CD11b, levels in MPs
were signiﬁcantly higher in CF than in PCD. Acute and intermittent patients
presented signiﬁcantly higher levels of CD11a- and CD66b-expressing MPs respect
to PCD patients. MPs are detectable in sputa obtained from CF patients and are
predominantly of granulocyte origin. The reason for a signiﬁcantly less presence
of granulocyte-derived MPs in PCD as compared with CF patients may be that
lung disease in PCD, although similar, is delayed in time as compared with CF.
This novel isolation method for MPs from sputum opens a new opportunity for the
study of lung pathology in CF.
213 Comparison of home and hospital intravenous antibiotic therapy
for acute pulmonary exacerbations in adults attending a regional
cystic ﬁbrosis centre
S. Kassim1, R. Naseer1, C. Etherington1, S. Conway1, D. Peckham1. 1St James’
University Hospital, Leeds, United Kingdom
Introduction: The aim of this study was to compare home vs. hospital treatment
for clinical outcomes in adult patients receiving intravenous antibiotics for acute
pulmonary exacerbations.
Methods: Case notes of patients who received intravenous antibiotic treatment for
an acute pulmonary exacerbation between 1st September 2008 and 31st August 2009
were reviewed retrospectively. Patients receiving part home/hospital therapy, those
on continuous intravenous antibiotic treatment and post lung transplant patients
were excluded. The ﬁrst treatment course for each patient was analysed. Clinical
outcome measures included lung function (FEV1, FVC), weight and inﬂammatory
markers (CRP, WCC, neutrophil). Best lung function and weight in 1 year pre
treatment were collected.
Results: 124 patients received 248 courses of treatment at home and 73 pa-
tients received 151 courses in hospital. No signiﬁcant differences in treatment
length, start FEV1 (hospital vs. home median 39% vs. 43%) or best FEV1
(median 61% vs. 57%). Start inﬂammatory markers were higher in hospital
patients. Signiﬁcant increase in FEV1 from start to end of treatment (hospital
39% to 53%, p< 0.001, home 43% to 50%, p = 0.04) but greater percentage change
in lung function in hospital treated patients (FEV1 9% vs. 3%, p< 0.001, FVC
11% vs. 4%, p< 0.0001). Baseline weight and BMI lower in hospital treated patients
(58 kg vs. 63.9 kg, p = 0.01; 21.2 vs. 22.4, p = 0.02). Median weight gain hospital vs.
home 1.1 vs. 0.2 kg, p = 0.003.
Conclusions: Both home and hospital treatment are associated with an increase in
lung function, but hospital treatment is superior with a greater percentage increase
in lung function and weight.
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Introduction: Clinical studies evaluating the rational use of the combination
of intravenous and aerosolized antibiotics (AB) in acute lung exacerbations are
scarce and conclude that this combination therapy is not superior compared to
intravenously administered therapy alone. The aim: compare 3 combinations of AB
regimes against Pseudomonas aeruginosa (Pa) in cystic ﬁbrosis (CF) patients with
lung exacerbation.
Methods: 108 CF patients (pts) with chronic Pa were prospectively randomized to
14 days of different AB courses: Group A − 32 pts (4−16 yrs) treated with TOBI
(16 pts) or Bramitob (16 pts), 300mg bid in combination with i.v. ceftazidime
and oral ciproﬂoxacin; Group B − 39 pts (6−17 yrs) treated with i.v. cefepime and
i.v. amikacin; Group C − 37 pts (4−17 yrs) treated with i.v. meropenem and i.v.
amikacin.
Results: All AB combinations signiﬁcantly improved clinical symptoms, lung
function and reduced sputum Pa density. Improvement of FVC in A, B and C
groups was +27.98%, +24.27% and +31.44%, respectively. Increase of FEV1 was
+ 37.17%, +28.85% and +40.6%, respectively. A group with inhaled tobramycins
was signiﬁcantly superior in decrease of Pa sputum density and even eradication
after treatment. In group A there was no growth of Pa sm. in 77.3% of patients, in
group B − 45.5%, in group C − 26%. Pa muc. completely disappeared from sputum
in group A in 79% of children, in group B − 25.8% and in group C − 29.1%.
Conclusion: Combination of inhaled form of tobramycin with oral ciproﬂoxacin
and i.v. ceftazidime for treatment of acute exacerbation in CF pts with chronic Pa
infection was superior compared to standard i.v. administered therapy.
